Latest news with #SecuritiesExchangeCommission
Yahoo
a day ago
- Business
- Yahoo
Cardiovascular Collaboration and Licensing Deals Report 2025: A Detailed Analysis of 589 Cardiovascular Deals from 2016 to 2025 - Key Players, Payments, and SEC Contracts Explored
The Cardiovascular Collaboration and Licensing Deals report details 589 biopharma agreements, analyzing financials, royalties, and deal structures. It includes links to actual contract documents, trends by therapeutic focus and technology, and insights into the most active dealmakers, offering critical benchmarking for future negotiations. Dublin, June 12, 2025 (GLOBE NEWSWIRE) -- The "Cardiovascular Collaboration and Licensing Deals 2016-2025" report has been added to Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the cardiovascular deals entered into by the worlds leading biopharma revised and updated, the report provides details of 589 cardiovascular deals from 2016 to report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their initial chapters of this report provide an orientation of cardiovascular dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in cardiovascular 3 covers the financial deal terms for deals signed in the cardiovascular field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty 4 provides a review of the top 25 most active biopharma companies in cardiovascular dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances 5 provides a comprehensive and detailed review of cardiovascular deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on 6 provides a comprehensive directory of cardiovascular deals listed by therapeutic report also includes numerous table and figures that illustrate the trends and activities in cardiovascular deal making since addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on Collaboration and Licensing Deals provides the reader with the following key benefits: Understand deal trends since 2016 Browse cardiovascular collaboration and licensing deals Benchmark analysis - identify market value of transactions Financials terms - upfront, milestone, royalties Directory of deals by company A-Z, therapy focus and technology type Leading deals by value Most active dealmakers Identify assets and deal terms for each transaction Access contract documents - insights into deal structures Due diligence - assess suitability of your proposed deal terms for partner companies Save hundreds of hours of research time Report ScopeCardiovascular Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of cardiovascular trends and structure of deals entered into by leading biopharma companies Collaboration and Licensing Deals includes: Trends in cardiovascular dealmaking in the biopharma industry Overview of collaboration and licensing deal structure Directory of cardiovascular deal records covering pharmaceutical and biotechnology The leading cardiovascular deals by value Most active cardiovascular licensing dealmakers In Cardiovascular Collaboration and Licensing Deals, the available deals are listed by: Company A-Z Headline value Therapeutic area Technology type Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where contract agreements allows due diligence of: What are the precise rights granted or optioned? What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? Key Topics Covered: Chapter 1 - IntroductionChapter 2 - Trends in cardiovascular dealmaking2.1. Introduction2.2. Cardiovascular partnering over the years2.3. Cardiovascular partnering by deal type2.4. Cardiovascular partnering by industry sector2.5. Cardiovascular partnering by stage of development2.6. Cardiovascular partnering by technology type2.7. Cardiovascular partnering by therapeutic indicationChapter 3 - Financial deal terms for cardiovascular partnering3.1. Introduction3.2. Disclosed financials terms for cardiovascular partnering3.3. Cardiovascular partnering headline values3.4. Cardiovascular deal upfront payments3.5. Cardiovascular deal milestone payments3.6. Cardiovascular royalty ratesChapter 4 - Leading cardiovascular deals and dealmakers4.1. Introduction4.2. Most active in cardiovascular partnering4.3. List of most active dealmakers in cardiovascular4.4. Top cardiovascular deals by valueChapter 5 - Cardiovascular contract document directory5.1. Introduction5.2. Cardiovascular partnering deals where contract document availableChapter 6 - Cardiovascular dealmaking by therapeutic target6.1. Introduction6.2. Deals by cardiovascular therapeutic targetDeal directory Deal directory - Cardiovascular deals by company A-Z 2016 to 2025 Deal directory - Cardiovascular deals by technology type 2016 to 2025 For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
05-06-2025
- Business
- Yahoo
Global Oncology Collaboration and Licensing Deals Report 2020-2025: 3,350 Biopharma Agreements Analyzed with Financial Terms, Partnering Trends, and Contract Insights
Dublin, June 05, 2025 (GLOBE NEWSWIRE) -- The "Oncology Collaboration and Licensing Deals 2020-2025" report has been added to Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the oncology deals entered into by the world's leading biopharma revised and updated, the report provides details of 3,350 oncology deals from 2020 to 2025. Oncology Collaboration and Licensing Deals provides the reader with the following key benefits: Understand deal trends since 2020 Browse oncology collaboration and licensing deals Benchmark analysis - identify market value of transactions Financials terms - upfront, milestone, royalties Directory of deals by company A-Z, therapy focus and technology type Leading deals by value Most active dealmakers Identify assets and deal terms for each transaction Access contract documents - insights into deal structures Due diligence - assess suitability of your proposed deal terms for partner companies Save hundreds of hours of research time Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do report contains a comprehensive listing of collaboration and licensing deals announced since 2020 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their contract agreements allows due diligence of: What are the precise rights granted or optioned? What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? 2,954 companies are featured in the report, including (sorted a-z): 1ST Biotherapeutics 2cureX 2seventy bio 3B Pharmaceuticals 3D Medicines 3SBio 3T Biosciences 4baseCare 4bases 4C Biomed 4D Path 4D Pharma 7 Hills Pharma 9 Meters Biopharma 48Hour Discovery 111 A*STAR Agency for Science Technology and Research A*STAR Bioprocessing Technology Institute A*STAR Singapore Immunology Network A*STAR' Institute of Molecular and Cell Biology A2 Biotherapeutics A2A Pharmaceuticals A3P Biomedical Aadi Bioscience Aarvik Therapeutics Abbisko Therapeutics Abbott Laboratories Abbvie Abcam AbCellera Biologics Abdul Latif Jameel Health AbelZeta Pharma Abera Bioscience Abilita Bio Abilita Therapeutics Abintus Bio Abiosciences Ablaze Pharmaceuticals ABL Bio Ab Magnitude Ventures Abound Bio Abpro Abramson Cancer Center AbSci AbTherx AbTis ABVC BioPharma Abveris ABX Academic Breast Cancer Consortium Accelerated Biosciences Accent Therapeutics Access to Comprehensive Genomic Profiling Coalition Acclinate Accuray AccuStem Sciences ACEA Therapeutics Acepodia Acerand Therapeutics Acerta Pharma Achilles Therapeutics Acibadem University Acrivon Therapeutics Acrotech Biopharma Actimed Therapeutics Actinium Pharmaceuticals ACT Therapeutics Actuate Therapeutics Acucela Acuitas Therapeutics Adagene AdAlta Adamis Pharmaceuticals Adaptimmune Adaptive Biotechnologies Adaptive Research AdaptVac Adcendo ADC Therapeutics Addario Lung Cancer Medical Institute AdhereTech Adimab Adlai Nortye Advancell Advaxis Advenchen Laboratories Aerogen Aethlon Medical Aethon Therapeutics Aetion Affimed Therapeutics Affini-T Therapeutics AGC Biologics Agena Bioscience Agencja Badan Medycznych Agendia Agenus Bio AgeX Therapeutics Agilent Technologies Agios Pharmaceuticals AgonOx AiCure Aidence Aidoc Aignostics AIkido Pharma AI Longevity AimedBio AIM ImmunoTech Ainos Aion Therapeutic AI Proteins Aitia AiVita Biomedical Ajax Therapeutics Ajinomoto Akamis Bio Akeso Biopharma Akoya Biosciences AKSO Biopharmaceutical Akston Biosciences Aktis Oncology Alamar Biosciences Albany Medical College Alberta Health Services Albert Einstein College of Medicine Alcedis Alchemab Alector Alessa Therapeutics Aleta Biotherapeutics Alex's Lemonade Stand Foundation Alibaba Health ALK Positive Alkyon Therapeutics All4Cure Allarity Therapeutics Allcyte Allelica Alliance for Cancer Gene Therapy Alliance Foundation Trials Alligator Bioscience Allist Pharma Allogene Overland Biopharm Allogene Therapeutics Alloplex Biotherapeutics Allorion Therapeutics Alloy Therapeutics Almac Diagnostics Almac Group Almirall Alopexx Alpha Biopharma Alpha Cancer Technologies Alphageneron Pharmaceuticals Alphamab Biopharmaceuticals Alphamab Oncology Alpha Tau Medical Alpine Immune Sciences Alteogen Alverno Clinical Laboratories Alvotech ALX Oncology Amasa Therapeutics Amazon Web Services Amber Pharmacy Ambry Genetics American Association for Cancer Research American Lung Association American Preclinical Services American Skin Association American Society of Clinical Oncology (ASCO) American Type Culture Collection (ATCC) Amgen AmMax Bio Amneal Pharmaceuticals Amoy Diagnostics Amphista Therapeutics AmplifyBio Amunix AnchorDx Angiogenesis Foundation Angle AnHeart Therapeutics Anima Biotech Anivive Lifesciences Anixa Biosciences Anji Pharma Anju Software Ankarys Therapeutics Ankyra Therapeutics Anocca AB Anova Enterprises Anpac Bio-Medical Science ANP Technologies Antengene Anthony Nolan Antisoma Therapeutics Antiverse Apeiron Biologics Apexigen Apmonia Therapeutics Apollomics Apollon Formularies Apollo Therapeutics Appia Bio Applied BioMath For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23-05-2025
- Business
- Yahoo
Molecular Diagnostics Collaboration and Licensing Agreements Analysis Report 2025 with Directory of 759 Deals Signed Since 2016 - Upfront, Milestone, Royalties Financial Terms
The report also includes numerous table and figures that illustrate the trends and activities in molecular diagnostics deal making since 2016. In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Dublin, May 23, 2025 (GLOBE NEWSWIRE) -- The "Molecular Diagnostics Collaboration and Licensing Deals 2016-2025" report has been added to revised and updated, the report provides details of molecular diagnostics deals from 2016 to report provides a detailed understanding and analysis of how and why companies enter molecular diagnostics deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Molecular Diagnostics Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the molecular diagnostics deals entered into by the world's leading biopharma companies. The report includes collaboration, development, research and licensing report contains a comprehensive listing of 759 molecular diagnostics deals announced since 2016 including financial terms where available including links to online deal records of actual molecular diagnostics partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their initial chapters of this report provide an orientation of molecular diagnostics 1 provides an introduction to the 2 provides an overview of the trends in molecular diagnostics dealmaking since 3 provides an overview of the leading molecular diagnostics deals since 2016. Deals are listed by headline 4 provides a comprehensive listing of the top 25 most active companies in molecular diagnostics dealmaking with a brief summary followed by a comprehensive listing of molecular diagnostics deals, as well as contract documents available in the public 5 provides a comprehensive and detailed review of molecular diagnostics deals signed and announced since Jan 2016, where a contract document is available in the public 6 provides a comprehensive and detailed review of molecular diagnostics partnering deals signed and announced since Jan 2016. The chapter is organized by specific molecular diagnostics technology type in Diagnostics Collaboration and Licensing Deals provides the reader with the following key benefits: Understand deal trends since 2016 Browse molecular diagnostics collaboration and licensing deals Benchmark analysis - identify market value of transactions Financials terms - upfront, milestone, royalties Directory of deals by company A-Z, deal type and therapy area Leading deals by value Most active dealmakers Identify assets and deal terms for each transaction Access contract documents - insights into deal structures Due diligence - assess suitability of your proposed deal terms for partner companies Save hundreds of hours of research time Molecular Diagnostics Collaboration and Licensing Deals includes: Trends in molecular diagnostics dealmaking in the biopharma industry Directory of molecular diagnostics deal records covering pharmaceutical and biotechnology The leading molecular diagnostics deals by value Most active molecular diagnostics licensing dealmakers Analyzing contract agreements allows due diligence of: What are the precise rights granted or optioned? What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? Key Topics Covered: Executive SummaryChapter 1 - IntroductionChapter 2 - Trends in molecular diagnostics dealmaking2.1. Introduction2.2. Molecular diagnostics deals over the years2.3. Most active molecular diagnostics dealmakers2.4. Molecular diagnostics deals by deal type2.5. Molecular diagnostics deals by therapy area2.6. Molecular diagnostics deals by industry sector2.7. Deal terms for molecular diagnostics deals2.7.1 Molecular diagnostics deals headline values2.7.2 Molecular diagnostics deal upfront payments2.7.3 Molecular diagnostics deal milestone payments2.7.4 Molecular diagnostics royalty ratesChapter 3 - Leading molecular diagnostics deals3.1. Introduction3.2. Top molecular diagnostics deals by valueChapter 4 - Most active molecular diagnostics dealmakers4.1. Introduction4.2. Most active molecular diagnostics dealmakers4.3. Most active molecular diagnostics deals company profilesChapter 5 - Molecular diagnostics contracts dealmaking directory5.1. Introduction5.2. Molecular diagnostics contracts dealmaking directoryChapter 6 - Molecular diagnostics dealmaking by technology typeDeal directory Deal directory - Molecular diagnostics deals by company A-Z Deal directory - Molecular diagnostics deals by deal type Deal directory - Molecular diagnostics deals by therapy area Deal type definitions For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Yahoo
23-05-2025
- Business
- Yahoo
Diagnostics Distribution Agreements Analysis Report 2025 with Directory of Deals Signed Since 2016 - Upfront, Milestone, Royalties Financial Terms, Company A-Z, Deal Type and Therapy Area
This report contains a comprehensive listing of distribution deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual distribution contract documents as submitted to the Securities Exchange Commission by companies and their partners. The report also includes numerous table and figures that illustrate the trends and activities in distribution dealmaking since 2016. In conclusion, this report provides everything a prospective dealmaker needs to know about distribution alliances. Dublin, May 23, 2025 (GLOBE NEWSWIRE) -- The "Distribution Deals in Diagnostics 2016 to 2025" report has been added to offering. The report provides access to distribution deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms. Distribution Deals in Diagnostics provides a detailed understanding and analysis of how and why companies enter distribution deals. Fully revised and updated, the report provides details of distribution deals from 2016 to 2025. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do deal directory includes a comprehensive listing of all distribution deals announced since 2016. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract initial chapters of this report provide an orientation of distribution dealmaking and business 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in distribution as well as a discussion on the merits of the type of 3 provides an overview of the structure of distribution 4 provides a review of the leading distribution deals since 2016. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances 5 provides a comprehensive listing of the top 25 most active distribution dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on report also includes numerous table and figures that illustrate the trends and activities in distribution dealmaking since 2016. In conclusion, this report provides everything a prospective dealmaker needs to know about distribution ScopeDistribution Deals in Diagnostics includes: Trends in distribution dealmaking in the biopharma industry Overview of distribution deal structure Directory of distribution deal records covering diagnostics The leading distribution deals by value Most active distribution dealmakers The leading distribution partnering resources In Distribution Deals in Diagnostics, the available deals are listed by: Company A-Z Headline value Therapeutic area Technology type Analyzing contract agreements allows due diligence of: What are the rights granted or optioned? What rights are granted by the agreement? What exclusivity is granted? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are intellectual property rights handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? Key Topics Covered: Chapter 1 - IntroductionChapter 2 - Trends in distribution dealmaking2.1. Introduction2.2. Definition of distribution deal2.3. Trends in distribution deals since 20162.3.1. Distribution dealmaking by year, 2016-20252.3.2. Distribution dealmaking by phase of development, 2016-20252.3.3. Distribution dealmaking by therapy area, 2016-20252.3.4. Distribution dealmaking by technology type, 2016-20252.3.5. Distribution dealmaking by most active company, 2016-20252.4. Reasons for entering into distribution partnering dealsChapter 3 - Overview of distribution deal structure3.1. Introduction3.2. Distribution agreement structureChapter 4 - Leading distribution deals4.1. Introduction4.2. Top distribution deals by valueChapter 5 - Top 25 most active distribution dealmakers5.1. Introduction5.2. Top 25 most active distribution dealmakersDeal directory Deal directory - distribution dealmaking by companies A-Z Deal directory - distribution dealmaking by therapy area Deal directory - distribution dealmaking by technology type For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Yahoo
23-05-2025
- Business
- Yahoo
Pharmaceuticals Collaboration Agreements Analysis Report 2025 with Directory of Deals Signed Since 2019 - Upfront, Milestone, Royalties Financial Terms, Company A-Z, Deal Type and Therapy Area
This report contains a comprehensive listing of collaboration deals announced since 2019 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual collaboration contract documents as submitted to the Securities Exchange Commission by companies and their partners. Dublin, May 23, 2025 (GLOBE NEWSWIRE) -- The "Collaboration Deals in Pharmaceuticals 2019-2025" report has been added to report provides access to collaboration deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms. Collaboration Deals in Pharmaceuticals provides a detailed understanding and analysis of how and why companies enter collaboration deals. Fully revised and updated, the report provides details of collaboration deals from 2019 to 2025. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not. The deal directory includes a comprehensive listing of all collaboration deals announced since 2019. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract initial chapters of this report provide an orientation of collaboration dealmaking and business 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in collaboration as well as a discussion on the merits of the type of 3 provides an overview of the structure of collaboration 4 provides a review of the leading collaboration deals since 2019. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances 5 provides a comprehensive listing of the top 25 most active collaboration dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on 6 provides a comprehensive and detailed review of collaboration deals organized by company A-Z, therapy, technology and industry type signed and announced since 2019 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the collaboration ScopeCollaboration Deals in Pharmaceuticals includes: Trends in collaboration dealmaking in the biopharma industry Overview of collaboration deal structure Directory of collaboration deal records covering pharmaceutical and biotechnology The leading collaboration deals by value Most active collaboration dealmakers The leading collaboration partnering resources In Collaboration Deals in Pharmaceuticals, the available deals are listed by: Company A-Z Headline value Therapeutic area Technology type Analyzing contract agreements allows due diligence of: What are the rights granted or optioned? What rights are granted by the agreement? What exclusivity is granted? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are intellectual property rights handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What subcollaboration and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? Key Topics Covered: Chapter 1 - IntroductionChapter 2 - Trends in collaboration dealmaking2.1. Introduction2.2. Definition of collaboration deal2.3. Trends in collaboration deals since 20192.3.1. Collaboration dealmaking by year, 2019-20252.3.2. Collaboration dealmaking by phase of development, 2019-20252.3.3. Collaboration dealmaking by industry sector, 2019-20252.3.4. Collaboration dealmaking by therapy area, 2019-20252.3.5. Collaboration dealmaking by technology type, 2019-20252.3.6. Collaboration dealmaking by most active company, 2019-20252.4. Reasons for entering into collaboration partnering deals2.5. The future of collaboration dealsChapter 3 - Overview of collaboration deal structure3.1. Introduction3.2. Collaboration agreement structureChapter 4 - Leading collaboration deals4.1. Introduction4.2. Top collaboration deals by valueChapter 5 - Top 25 most active collaboration dealmakers5.1. Introduction5.2. Top 25 most active collaboration dealmakersChapter 6 - Collaboration deals including contracts directory6.1. Introduction6.2. Collaboration deals with contracts 2019-2025Deal directory Deal directory - collaboration dealmaking by companies A-Z Deal directory - collaboration dealmaking by therapy area Deal directory - collaboration dealmaking by technology type For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
